
Draig Therapeutics, a Welsh clinical-stage company developing glutamate and GABA-based treatments for neuropsychiatry, has appointed Ivana Magovčević-Liebisch as President and …
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner

